Results 91 to 100 of about 14,228 (116)

Umbralisib antagonizes multidrug resistance in ABCB1-overexpressing cancer cells. [PDF]

Front Oncol
Bo L, Zhang B, Chen XY, Mao X, Zhong L, Tan M, Cui M, Patel H, Wurpel JND, Chen ZS.   +9 more
europepmc   +1 more source

Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. [PDF]

Clin Med Insights Oncol
Zheng H, Wen F, Wu B.
europepmc   +1 more source

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial. [PDF]

Neurooncol Adv
Ozer BH, Cohen AL, Colman H, Penas-Prado M, de Groot J, Loghin ME, Pan E, Raizer JJ, Kumthekar P, Fink KL, Walbert T, Merrell RT, Groves MD, Ahluwalia MS, Wu J, Burton EC, Vera E, Mendoza T, Grajkowska E, Wall K, Reyes J, Yuan Y, Armstrong TS, Gilbert MR.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database

Expert Opinion on Drug Metabolism and Toxicology, 2023
Bin Zhao, Wugeng Cui
exaly  

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

Annals of Oncology, 2006
Peter Martus, A Korfel, K Jahnke
exaly  

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules

Annals of Oncology, 2002
Alan V. Boddy, Andreas Schätzlein, A H Calvert   +2 more
exaly  

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

Annals of Oncology, 2004
W Ten Bokkel Huinink
exaly